| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.67▲ | 1.67▲ | 1.68▲ | 1.69▲ | 1.73▼ |
| MA10 | 1.68▲ | 1.68▲ | 1.69▲ | 1.67▲ | 1.82▼ |
| MA20 | 1.73▼ | 1.78▼ | 1.79▼ | 1.73▼ | 1.85▼ |
| MA50 | 1.85▼ | 1.95▼ | 1.95▼ | 1.88▼ | 2.08▼ |
| MA100 | 1.93▼ | 1.89▼ | 1.88▼ | 1.85▼ | N/A |
| MA200 | 1.94▼ | 2.19▼ | 2.16▼ | 2.01▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.005▲ | -0.001▼ | -0.004▼ | 0.005▲ | -0.008▼ |
| RSI | 42.819▼ | 39.346▼ | 39.392▼ | 43.307▼ | 40.539▼ |
| STOCH | 44.743 | 36.621 | 32.737 | 58.382 | 28.386 |
| WILL %R | -32.900 | -72.612 | -72.612 | -41.579 | -73.253 |
| CCI | 44.025 | -36.225 | -44.374 | -48.174 | -106.311▼ |
|
Monday, April 27, 2026 04:45 AM
Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented Biomarker analyses from the ongoing Phase 3 study evaluating ...
|
|
Tuesday, April 21, 2026 04:58 AM
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line models Immune cells ...
|
|
Monday, April 20, 2026 06:07 AM
Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preservedIdentification of ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 28/04/26 | 1.6327 | 1.692 | 1.6327 | 1.692 | 1,351 |
| 27/04/26 | 1.6978 | 1.6978 | 1.6978 | 1.6978 | 454 |
| 24/04/26 | 1.70 | 1.71 | 1.655 | 1.6971 | 2,054 |
| 23/04/26 | 1.675 | 1.675 | 1.675 | 1.675 | 0 |
| 22/04/26 | 1.65 | 1.7139 | 1.63 | 1.675 | 3,918 |
| 21/04/26 | 1.7144 | 1.7144 | 1.655 | 1.655 | 1,004 |
| 20/04/26 | 1.67 | 1.72 | 1.60 | 1.60 | 2,651 |
| 17/04/26 | 1.66 | 1.71 | 1.66 | 1.70 | 3,294 |
| 16/04/26 | 1.47 | 1.77 | 1.47 | 1.60 | 3,673 |
| 15/04/26 | 1.70 | 1.85 | 1.6801 | 1.7571 | 9,728 |
|
|
||||
|
|
||||
|
|